Citigroup’s Theseus Pharmaceuticals, Inc. Common Stock THRX Stock Holding History

Citigroup’s Portfolio THRX Stock Details THRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-2,876	Closed	-$11.6K	–	5936
2023 Q4	$11.6K	Buy	2,876 +2,861	+19,073%	+$8.73K	﹤0.01%	5156
2023 Q3	$40	Sell	15 -6,014	-100%	-$23.6K	﹤0.01%	5544
2023 Q2	$56.3K	Buy	+6,029	New	+$59.4K	﹤0.01%	4574
2023 Q1	–	Sell	-115	Closed	-$573	–	5963
2022 Q4	$573	Sell	115 -142	-55%	-$832	﹤0.01%	5490
2022 Q3	$1K	Sell	257 -916	-78%	-$6.47K	﹤0.01%	5720
2022 Q2	$6K	Buy	1,173 +724	+161%	+$5.98K	﹤0.01%	5579
2022 Q1	$5K	Sell	449 -2,698	-86%	-$28.8K	﹤0.01%	5856
2021 Q4	$40K	Buy	+3,147	New	+$47.5K	﹤0.01%	5181

Citigroup's THRX Position: Q1 2024 in Review

Citigroup sold out of Theseus Pharmaceuticals, Inc. Common Stock (THRX) in Q1 2024, closing a stake of 2,876 shares — an estimated $11.6K sold.

Citigroup first reported a position in THRX in Q4 2021 and held it in 8 quarters. The position peaked at $56.3K in Q2 2023. 1 fund tracked by Wall St. Rank holds THRX as of Q1 2024.

Citigroup reported no remaining Theseus Pharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Citigroup sold 2,876 Theseus Pharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $11.6K.
Citigroup first reported a position in Theseus Pharmaceuticals, Inc. Common Stock in Q4 2021 and held it in 8 quarters.
Citigroup's Theseus Pharmaceuticals, Inc. Common Stock position peaked at $56.3K in Q2 2023.
1 fund tracked by Wall St. Rank held Theseus Pharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.